Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
NCT05288283 · Jazz Pharmaceuticals · PHASE3 · terminated · last registry update 2025-02-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated due to a business decision.” | – | Registry record, Jazz Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CNR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-01-16Results posted on the registry: Mayo Clinic, Cannabidiol + Placebo Administration (NCT05388058)
- 2026-01-08Phase 3 first posted: University of Oxford, CBD 100 mg/mL Oral Solution + Placeb (NCT07326124)
- 2025-12-09Results posted on the registry: Dartmouth-Hitchcock Medical Center, Marijuana + Dronabinol (NCT01964404)
- 2025-11-26Results posted on the registry: Yale University, CBD Day 1 + CBD Day 2 (NCT05076370)
- 2025-11-24Phase 3 first posted: Khon Kaen University, 10% urea lotion plus 1% cannabidiol + Control (NCT07245238)
- 2025-11-17Phase 3 first posted: Mayo Clinic, Dronabinol + Placebo (NCT07231965)
- 2025-10-31Results posted on the registry: Jazz Pharmaceuticals, GWP42003-P (NCT04485104)
- 2025-10-31Also stopped (terminated): Jazz Pharmaceuticals, GWP42003-P (NCT04485104)
- 2025-10-20Results posted on the registry: Cardiol Therapeutics Inc., CardiolRx (NCT05494788)
- 2025-10-15Results posted on the registry: Albert Einstein College of Medicine, Cannabis (NCT03633721)
- 2025-09-11Results posted on the registry: Defined Research, Defined CBD + Placebo (NCT05233761)
- 2025-08-29Phase 3 first posted: Johns Hopkins University, Cannabidiol (CBD) + Placebo (NCT07148843)
- 2025-08-29Phase 3 first posted: Montefiore Medical Center, Dronabinol Capsules + Epidiolex 100 mg/mL Oral Solution (NCT07148206)
- 2025-08-19Results posted on the registry: Yale University, [18F]FPEB with PET (NCT05664763)
- 2025-08-19Also stopped (terminated): Yale University, [18F]FPEB with PET (NCT05664763)
- 2025-08-14Phase 3 first posted: Wayne State University, Low-Dose Cannabidiol + Placebo Matched to Moderate-Dose Cannabidiol (NCT07123467)
- 2025-08-14Results posted on the registry: Medical University of South Carolina, Cannabidiol (NCT05317546)
- 2025-08-07Results posted on the registry: University of Florida, oral cannabinoid + oral codeine/acetaminophen (NCT05477875)
- 2025-08-06Results posted on the registry: University of Florida, Active CBD + Vehicle Control (Placebo) (NCT04586712)
- 2025-08-01Results posted on the registry: University of California, Los Angeles, Cannabidiol (CBD) 600 mg + Placebo (NCT03787628)
- 2025-07-31Results posted on the registry: Food and Drug Administration (FDA), Cannabidiol + Placebo (NCT06192589)
- 2025-07-29Results posted on the registry: Dana-Farber Cancer Institute, Cannabidiol (NCT04482244)
- 2025-07-25Results posted on the registry: Cardiol Therapeutics Inc., Cannabidiol, pharmaceutically produced with < 5 ppm THC + Placebo (NCT04615949)
- 2025-07-03Results posted on the registry: University of Virginia, CBD + Shea Butter (NCT04611347)
- 2025-06-11Results posted on the registry: The University of Texas Health Science Center, Houston, Standard of Care (acetaminophen +naproxen +gabapentin + as needed oxycodone or Tramadol) + Dronabinol (NCT05820685)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision